Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
103 Results for "
vascular endothelial growth factor receptor
" in MedChemExpress (MCE) Product Catalog:
Products (103)
103 Results for "vascular endothelial growth factor receptor" in MCE Product Catalog:
10
10 Cited Publications
Synonyms: AV-951; KRN951
Tivozanib (AV-951; KRN951) is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib exhibits antitumor efficacy .
10
10 Cited Publications
Synonyms: AV-951 hydrochloride hydrate; KRN951 hydrochloride hydrate
Tivozanib hydrochloride hydrate is the hydrate hydrochloride form of Tivozanib (HY-10977). Tivozanib hydrochloride hydrate is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib hydrochloride hydrate exhibits antitumor efficacy .
10
10 Cited Publications
Synonyms: AV-951 hydrate; KRN951 hydrate
Tivozanib hydrate (AV-951 hydrate; KRN951 hydrate) is the hydrate form of Tivozanib (HY-10977). Tivozanib hydrate is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib hydrate exhibits antitumor efficacy .
4
4 Cited Publications
Research Areas:
Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction .
3
3 Cited Publications
Cat. No.: HY-P70147
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: NRP1; Transmembrane receptor; Neuropilin 1; CD304 Antigen; VEGF165R; DKFZp686M1967; NRP; Neuropilin; Neuropilin-1; BDCA4; CD304; NP1; vascular endothelial Cell growth factor 165 receptor
Species:
Human
Source:
HEK293
2
2 Cited Publications
Cat. No.: HY-P81643
Synonyms: KDR; FLK1; VEGFR2; vascular endothelial growth factor receptor 2; VEGFR-2; Fetal liver kinase 1; FLK-1; Kinase insert domain receptor; KDR; Protein-tyrosine kinase receptor flk-1; CD antigen CD309
1
Target:
Research Areas:
Acrizanib (LHA510) is a small-molecule vascular endothelial growth factor receptor 2 (VEGFR-2, KDR) inhibitor. Acrizanib inhibits the proliferation of BaF3-Tel-KDR cells dependent on VEGFR-2 activity, with an IC50 of 17.4 nM. Acrizanib can be used in research related to choroidal neovascularization and neovascular age-related macular degeneration .
1
1 Cited Publications
Cat. No.: HY-P70636
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: FLT1; Tyrosine-Protein Kinase FRT; Prev. FLT; FLT-1; vascular endothelial growth factor receptor 1; vascular endothelial growth factor receptor 1 Variant; VEGFR1; Platelet-Derived growth factor receptor-Like Protein; vascular Permeability factor receptor
Species:
Human
Source:
HEK293
1
1 Cited Publications
Cat. No.: HY-P70552
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: KDR; Fetal Liver Kinase 1; Kinase Insert Domain receptor; vascular endothelial growth factor receptor 2 Variant; vascular endothelial growth factor receptor 2; Tyrosine Kinase growth factor receptor; VEGFR2; receptor Protein-Tyrosine Kinase; FLK1; Fetal L
Species:
Human
Source:
HEK293
Synonyms: ANG-3070
Research Areas:
Ansornitinib is an orally active dual kinase inhibitor that inhibits platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR2). Ansornitinib can be used as an antifibrotic agent in lung, liver, kidney, and gastrointestinal fibrotic diseases .
Synonyms: SIM010603
Tafetinib (SIM010603) is an oral multi-targets receptor tyrosine kinases inhibitor. Tafetinib inhibitsstem cell factor receptor (Kit),vascular endothelial growth factor receptor-2 (VEGFR-2),platelet-derived growth factor receptor-β (PDGFR-β),glial cell line-derived neurotrophic factor receptor (Rearranged during Transfection; RET), andFms-like tyrosine kinase-3 (FLT3)withIC50values between 5.0 and 68.1 nmol/l. Tafetinib inhibits the phosphorylation ofPDGFR-βandVEGFR-2. Tafetinib inhibits endothelial cell proliferation, endothelial cells chemotaxis, and corneal angiogenesis .
Cat. No.: HY-P3318
CAS No.: 73572-58-4
Synonyms: L-BOC2
Target:
Research Areas:
Cat. No.: HY-P99516
CAS No.: 2250342-36-8
Synonyms: HLX-06
Cat. No.: HY-177134
CAS No.: 2243235-80-3
Target:
Research Areas:
Taligantinib (Compound Example 70) is an orally active and selective dual inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2) and hepatocyte growth factor receptor (c-Met). Taligantinib suppresses tumor angiogenesis and cell proliferation. Taligantinib is promising for research of solid tumors such as non-small cell lung cancer and hepatocellular carcinoma .
Cat. No.: HY-10338A
CAS No.: 1226999-07-0
Target:
Research Areas:
Foretinib phosphate is an orally bioavailable small molecule with potential anti-tumor activity. Foretinib phosphate can selectively inhibit hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), thereby potentially inhibiting tumor angiogenesis, tumor cell proliferation and metastasis. Foretinib phosphate shows different anti-cancer activity from cabozantinib in lung cancer cells and has stronger inhibitory effects on targets such as MEK1/2, FER and AURKB .
Cat. No.: HY-120200
CAS No.: 1951466-83-3
Target:
Research Areas:
YF-452 is a potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2). YF-452 remarkably inhibits the migration, invasion and tube-like structure formation of human umbilical vein endothelial cells (HUVECs) with little toxicity. YF-452 inhibits VEGF-induced phosphorylation of VEGFR2 kinase and the downstream protein kinases including extracellular signal regulated kinase (ERK), focal adhesion kinase (FAK) and Src. YF-452 is a potential antiangiogenic agent candidate for cancer research .
Cat. No.: HY-P10833
Cat. No.: HY-157420
CAS No.: 3020790-57-9
Target:
Research Areas:
VEGFR-2-IN-38 (compound 3) is a potential vascular endothelial growth factor receptor-2 inhibitor .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
